Javascript must be enabled to continue!
Temporal trends in the incidence and mortality of pulmonary arterial hypertension in the United Kingdom over the past 3 decades
View through CrossRef
Abstract
Introduction
Pulmonary arterial hypertension (PAH) imposes significant burden due to the associated morbidity and mortality. Evaluating the temporal trends in the incidence and mortality of PAH is of paramount importance as it enables risk stratification and prompt recognition of emerging trends.
Methods
Temporal trends in the incidence and mortality of PAH in the United Kingdom (UK) over the period 1990-2019 were evaluated by retrieving data, including the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR), from the Global Burden of Disease database. Joinpoint Analysis was utilized tocalculate the Annual Percent Change (APC) and the Average Annual Percent Change(AAPC). Trends were evaluated across the UK, the 4 nations within the UK (England,Wales, Northern Ireland, and Scotland), and across the different regions within England.
Results
Over a span of 30 years, an estimated total of 6,942 cases of PAH with a female predominance 53.9% were reported across the UK. A statistically significant decline in the ASIR across the UK was noted with an AAPC of -0.16 (95%CI -0.17 to -0.15, p<0.001). Gender stratification revealed a statistically significant decline in the ASIR in both males and females, with the more prominent decrease noted in the latter with an AAPC of -0.23. Stratification on a national level revealed a statistically significant decrease in the ASIR across England, Scotland, Northern Ireland, and Wales
with the highest decline observed in Wales with an AAPC of -0.44 (95CI% -0.45 to -0.44, p<0.001). Across England, a statistically significant decline was noted in all of the regions, except for North West England which encountered a statistically insignificant decline with an AAPC of -0.014 (95CI% -0.31 to 0.006, p=0.14). In terms of PAH-related mortalities, an estimated total of 3,381 deaths with a female predominance of 66.6% were reported. A statistically significant decline in the ASMR was noted across the UK with an AAPC of -0.84 (95%CI -0.92 to -0.77, p<0.001). Gender stratification revealed a statistically significant decline in both females and males, with the more prominent decline noted in the latter. Stratification on a national level revealed a statistically significant decline across all 4 nations, with the most prominent decline noted in Northern Ireland with an AAPC of -1.12 (95%CI -1.30 to -1.02, p<0.001). Across England, a statistically significant decline was noted across all regions, with Greater London witnessing the greatest decline with an AAPC of -1.21.
Conclusion
During 1990-2019, pulmonary arterial hypertension has witnessed a statistically significant decline in incidence and mortality across the UK. These findingswarrant comparison with other developed and developing countries to identify the factors leading to such promising decline.
Oxford University Press (OUP)
Title: Temporal trends in the incidence and mortality of pulmonary arterial hypertension in the United Kingdom over the past 3 decades
Description:
Abstract
Introduction
Pulmonary arterial hypertension (PAH) imposes significant burden due to the associated morbidity and mortality.
Evaluating the temporal trends in the incidence and mortality of PAH is of paramount importance as it enables risk stratification and prompt recognition of emerging trends.
Methods
Temporal trends in the incidence and mortality of PAH in the United Kingdom (UK) over the period 1990-2019 were evaluated by retrieving data, including the age-standardized incidence rate (ASIR) and the age-standardized mortality rate (ASMR), from the Global Burden of Disease database.
Joinpoint Analysis was utilized tocalculate the Annual Percent Change (APC) and the Average Annual Percent Change(AAPC).
Trends were evaluated across the UK, the 4 nations within the UK (England,Wales, Northern Ireland, and Scotland), and across the different regions within England.
Results
Over a span of 30 years, an estimated total of 6,942 cases of PAH with a female predominance 53.
9% were reported across the UK.
A statistically significant decline in the ASIR across the UK was noted with an AAPC of -0.
16 (95%CI -0.
17 to -0.
15, p<0.
001).
Gender stratification revealed a statistically significant decline in the ASIR in both males and females, with the more prominent decrease noted in the latter with an AAPC of -0.
23.
Stratification on a national level revealed a statistically significant decrease in the ASIR across England, Scotland, Northern Ireland, and Wales
with the highest decline observed in Wales with an AAPC of -0.
44 (95CI% -0.
45 to -0.
44, p<0.
001).
Across England, a statistically significant decline was noted in all of the regions, except for North West England which encountered a statistically insignificant decline with an AAPC of -0.
014 (95CI% -0.
31 to 0.
006, p=0.
14).
In terms of PAH-related mortalities, an estimated total of 3,381 deaths with a female predominance of 66.
6% were reported.
A statistically significant decline in the ASMR was noted across the UK with an AAPC of -0.
84 (95%CI -0.
92 to -0.
77, p<0.
001).
Gender stratification revealed a statistically significant decline in both females and males, with the more prominent decline noted in the latter.
Stratification on a national level revealed a statistically significant decline across all 4 nations, with the most prominent decline noted in Northern Ireland with an AAPC of -1.
12 (95%CI -1.
30 to -1.
02, p<0.
001).
Across England, a statistically significant decline was noted across all regions, with Greater London witnessing the greatest decline with an AAPC of -1.
21.
Conclusion
During 1990-2019, pulmonary arterial hypertension has witnessed a statistically significant decline in incidence and mortality across the UK.
These findingswarrant comparison with other developed and developing countries to identify the factors leading to such promising decline.
Related Results
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Respiratory rate modulation improves symptoms in patients with pulmonary hypertension
Respiratory rate modulation improves symptoms in patients with pulmonary hypertension
Background: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are chronic diseases with a severe symptom burden. Common symptoms are dyspnoea at lig...
Pulmonary hypertension associated with left-sided heart disease
Pulmonary hypertension associated with left-sided heart disease
Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence ...
Principles of pharmacological correction of pulmonary arterial hypertension
Principles of pharmacological correction of pulmonary arterial hypertension
Definition and classification: Pulmonary hypertension (PH) is a group of life-threatening progressive diseases of various genesis, characterized by a progressive increase in arteri...
Hypertension related vs diabetes related cardiovascular deaths which is the bigger killer? a USA mortality trend analysis using CDC WONDER
Hypertension related vs diabetes related cardiovascular deaths which is the bigger killer? a USA mortality trend analysis using CDC WONDER
Abstract
Background
Cardiovascular (CV) mortality remains a leading cause of death worldwide, with hypertension and diabe...
Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects.
Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects.
In patients with pulmonary hypertension associated with congenital heart defects, ultrastructural abnormalities are observed in endothelial cells, which suggest heightened metaboli...
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...

